|
Delayed
NSE India S.E.
09:57:49 02/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 1,956.60 INR | -1.56% |
|
+0.17% | +37.84% |
| 08-14 | Ipca Laboratories Limited, Q1 2027 Earnings Call, Aug 14, 2026 | |
| 08-13 | Ipca Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
Company Valuation: Ipca Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 270,385 | 205,589 | 313,934 | 381,038 | 406,231 | 504,263 | - | - |
| Change | - | -23.96% | 52.7% | 21.38% | 6.61% | 24.13% | - | - |
| Enterprise Value (EV) 1 | 275,070 | 201,870 | 325,349 | 391,231 | 408,673 | 493,613 | 484,306 | 472,119 |
| Change | - | -26.61% | 61.17% | 20.25% | 4.46% | 20.78% | -1.89% | -2.52% |
| P/E | 30.6x | 43.6x | 57.4x | 51.6x | 35.6x | 33.2x | 28.4x | 24.8x |
| PBR | 4.92x | 2.58x | 4.96x | 5.48x | 5.04x | 5.29x | 4.55x | 3.89x |
| PEG | - | -0.9x | 3.6x | 1.5x | 0.7x | 1x | 1.7x | 1.7x |
| Capitalization / Revenue | 4.64x | 3.29x | 4.07x | 4.26x | 4.21x | 4.59x | 4.11x | 3.71x |
| EV / Revenue | 4.72x | 3.23x | 4.22x | 4.38x | 4.24x | 4.49x | 3.95x | 3.47x |
| EV / EBITDA | 21x | 21.8x | 24.6x | 22.7x | 20.7x | 19.6x | 16.6x | 14.2x |
| EV / EBIT | 25.6x | 30.3x | 33.8x | 29.5x | 26.2x | 24x | 20.5x | 17.4x |
| EV / FCF | 72.9x | 64.8x | 60.9x | 71.7x | 83.5x | 63.1x | 40.1x | 30.1x |
| FCF Yield | 1.37% | 1.54% | 1.64% | 1.4% | 1.2% | 1.59% | 2.49% | 3.32% |
| Dividend per Share 2 | 8 | 4 | 4 | 2 | 6 | 5.769 | 6.185 | 7.114 |
| Rate of return | 0.75% | 0.49% | 0.32% | 0.13% | 0.37% | 0.29% | 0.31% | 0.36% |
| EPS 2 | 34.85 | 18.58 | 21.57 | 29.08 | 44.98 | 59.87 | 69.92 | 80.13 |
| Distribution rate | 23% | 21.5% | 18.5% | 6.88% | 13.3% | 9.64% | 8.84% | 8.88% |
| Net sales 1 | 58,298 | 62,443 | 77,050 | 89,396 | 96,463 | 109,955 | 122,660 | 136,008 |
| EBITDA 1 | 13,073 | 9,268 | 13,212 | 17,261 | 19,786 | 25,244 | 29,171 | 33,139 |
| EBIT 1 | 10,748 | 6,652 | 9,639 | 13,283 | 15,604 | 20,577 | 23,583 | 27,169 |
| Net income 1 | 8,841 | 4,713 | 5,474 | 7,377 | 11,411 | 15,145 | 17,797 | 20,425 |
| Net Debt 1 | 4,685 | -3,720 | 11,415 | 10,193 | 2,442 | -10,650 | -19,956 | -32,144 |
| Reference price 2 | 1,065.75 | 810.35 | 1,237.40 | 1,501.90 | 1,601.20 | 1,987.60 | 1,987.60 | 1,987.60 |
| Nbr of stocks (in thousands) | 253,704 | 253,704 | 253,704 | 253,704 | 253,704 | 253,704 | - | - |
| Announcement Date | 24/05/22 | 29/05/23 | 29/05/24 | 29/05/25 | 29/05/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.2x | 4.49x | 19.55x | 0.29% | 5.31B | |
| 33.02x | 11.99x | 24.3x | 0.6% | 1,034B | |
| 29.7x | - | - | 1.98% | 654B | |
| 33.18x | 7.69x | 15.99x | 2.64% | 459B | |
| 19.36x | 4.61x | 11.42x | 2.88% | 343B | |
| 22.91x | 5.89x | 14.6x | 2.71% | 307B | |
| 20.82x | 4.27x | 12.21x | 2.06% | 251B | |
| 27.71x | 7.15x | 12.7x | 2.3% | 237B | |
| 13.18x | 4.74x | 9.88x | 3.82% | 202B | |
| -45.81x | 6.6x | 25.78x | 2.2% | 186B | |
| Average | 18.73x | 6.38x | 16.27x | 2.15% | 367.69B | |
| Weighted average by Cap. | 24.09x | 8.03x | 17.80x | 1.95% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- IPCALAB Stock
- Valuation Ipca Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
